These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9523733)

  • 1. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
    van Tellingen O; Punt CJ; Awada A; Wagener DJ; Piccart MJ; Groot Y; Schaaf LJ; Henrar RE; Nooijen WJ; Beijnen JH
    Cancer Chemother Pharmacol; 1998; 41(5):377-84. PubMed ID: 9523733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule.
    Awada A; Punt CJ; Piccart MJ; Van Tellingen O; Van Manen L; Kerger J; Groot Y; Wanders J; Verweij J; Wagener DJ
    Br J Cancer; 1999 Mar; 79(9-10):1454-61. PubMed ID: 10188890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue.
    Li LH; DeKoning TF; Kelly RC; Krueger WC; McGovren JP; Padbury GE; Petzold GL; Wallace TL; Ouding RJ; Prairie MD
    Cancer Res; 1992 Sep; 52(18):4904-13. PubMed ID: 1516047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
    van Tellingen O; Nooijen WJ; Schaaf LJ; van der Valk M; van Asperen J; Henrar RE; Beijnen JH
    Cancer Res; 1998 Jun; 58(11):2410-6. PubMed ID: 9622082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma.
    van Tellingen O; Pels EM; Henrar RE; Schaaf LJ; Padbury GE; Beijnen JH; Nooijen WJ
    J Chromatogr; 1994 Jan; 652(1):51-8. PubMed ID: 8014227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244).
    Vries JD; Doppenberg WG; Henrar RE; Bult A; Beijnen JH
    J Pharm Sci; 1996 Nov; 85(11):1227-33. PubMed ID: 8923330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
    Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR
    Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
    Kestell P; Dunlop IC; McCrystal MR; Evans BD; Paxton JW; Gamage RS; Baguley BC
    Cancer Chemother Pharmacol; 1999; 44(1):45-50. PubMed ID: 10367748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of high-dose zidovudine administered as a continuous infusion in patients with cancer.
    Marchbanks K; Dudley MN; Posner MR; Darnowski J
    Pharmacotherapy; 1995; 15(4):451-7. PubMed ID: 7479197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ; Wiegand RA; LoRusso PM; Baker LH
    Clin Cancer Res; 1995 Aug; 1(8):831-7. PubMed ID: 9816052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
    Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK
    Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical development of a parenteral formulation of the novel anti-tumor agent carzelesin (U-80,244).
    Jonkman-de Vries JD; de Graaff-Teulen MJ; Henrar RE; Kettenes-van den Bosch JJ; Bult A; Beijnen JH
    Invest New Drugs; 1994; 12(4):303-14. PubMed ID: 7775131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
    Zackrisson AL; Malmström H; Peterson C
    Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
    Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
    Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).
    Jonkman-De Vries JD; Rosing H; Henrar RE; Bult A; Beijnen JH
    PDA J Pharm Sci Technol; 1995; 49(6):283-8. PubMed ID: 8581459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection.
    Embree L; Gelmon K; Tolcher A; Hudon N; Heggie J; Dedhar C; Logan P; Bally MB; Mayer LD
    Cancer Chemother Pharmacol; 1998; 41(5):347-52. PubMed ID: 9523729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
    Mross K; Hüttmann A; Herbst K; Hanauske AR; Schilling T; Manegold C; Burk K; Hossfeld DK
    Cancer Chemother Pharmacol; 1996; 38(3):217-24. PubMed ID: 8646795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.